The S&P 500 index fell by 1.95% during the trading week ending October 16, 2026, closing at 7,659.44. This level remains just over 2% below its all-time high reached earlier that month, indicating a slight pullback in the market. Economic forecasts remain stable, with the Atlanta Fed's GDPNow tool maintaining a 3.6% real GDP growth projection for the U.S. in the third quarter of 2026. The CME Group's FedWatch Tool outlook also showed little change, suggesting steady expectations for Federal Reserve policy in the near term.
For readers following the S&P 500's recent performance, here is Pluang's market snapshot as of Oct 19, 2026 19:41 WIB: Among 150 priced US stocks tradable on Pluang, 77 rose and 70 fell today. Notable movers include QCOM (QUALCOMM, Inc.) at USD 176.53 with a 1-day change of +2.57%, NOK (Nokia Corp) at USD 9.36 with +2.41%, and TSM (Taiwan Semiconductor Mfg. Co. Ltd.) at USD 422.41 with +2.38%.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
